Drug intelligence / Profile preview

SenL_19

Development stage: Phase 2
Lead developer: Senlang Bio
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

**SenL_19** is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Hebei Senlang Biotechnology for relapsed/refractory B-cell malignancies. It consists of patient-derived T cells genetically engineered using a lentiviral vector to express a CAR targeting **CD19**, a surface antigen on B cells, enabling specific recognition and lysis of malignant B cells. Administered via intravenous infusion following lymphodepleting chemotherapy (e.g., fludarabine), it is primarily indicated for **B-cell acute lymphoblastic leukemia (B-ALL)** and under evaluation for **lymphoma** and **non-Hodgkin lymphoma**.

Other names: Senl-h19Senl-h-19Senl-h 19

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on SenL_19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SenL_19.

Explore the full profile